New drug made available outside clinical trials for patients in need
NCT ID NCT07647627
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program allows certain patients to receive dibotatug (DR-01) even if they cannot join a clinical trial. It is only for those with a doctor's request and who meet specific criteria. The goal is to provide access to a potential treatment when no other options are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dibotatug (DR-01)
- What this could lead to
- If this program helps patients, it could provide early access to a potential treatment for those with no other options.
- What could go wrong
- This is an expanded access program, not a clinical trial, so there is no guarantee of benefit. Risks are not fully known and may include serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new related studies are added.
By submitting, you agree to our Terms of use